Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Holding ANIK?
Track your performance easily
ANIK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.00 - $29.12
Previous Close$17.2
Volume108.87K
Average Volume (3M)85.54K
Market Cap
$251.90M
Enterprise Value$186.42M
Total Cash (Recent Filing)$90.72M
Total Debt (Recent Filing)$25.24M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Feb 20, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.64
Shares Outstanding14,645,596
10 Day Avg. Volume131,508
30 Day Avg. Volume85,542
Standard Deviation0.11
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)1.52
Price to Cash Flow (P/CF)12.40
P/FCF Ratio19.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit1.81
Enterprise Value/Ebitda-8.26
Forecast
1Y Price Target
$25.00Price Target Upside41.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anika Therapeutics News
PremiumCompany Announcements
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
PremiumCompany Announcements
Anika Therapeutics Focuses on Core Growth Amid Restructuring
PremiumCompany Announcements
Anika Therapeutics Refocuses on Core Technology and Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnika is expected to generate $0.30 in non-GAAP EPS, outperforming the consensus GAAP EPS estimate of -$0.01.
Market ExpansionThe upcoming U.S. commercial launches of Cingal and Hyalofast could have a significant financial impact.
Product DevelopmentPotential needle-mover products Cingal and Hyalofast have completed pivotal trials.
Bears Say
Financial PerformanceAnika generated $38.8 million in revenue, which fell short of both the company's and the consensus estimates.
Guidance And OutlookManagement significantly reduced its previous adjusted EBITDA guidance for the fiscal year, reflecting a more pessimistic outlook.
Regulatory ChallengesCingal has faced regulatory delays with slow-moving conversations with the FDA.
---
Ownership Overview
3.21% Insiders
15.18% Mutual Funds
35.91% Other Institutional Investors
33.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $16.00 and its highest was $29.11 in the past 12 months.
What is Anika Therapeutics’s market cap?
Currently, no data Available
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 85 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.34.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -$0.23.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 14,645,596 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -30.673%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Among the largest hedge funds holding Anika Therapeutics’s share is Diker Management LLC. It holds Anika Therapeutics’s shares valued at 1M.
---
Anika Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (41.08% Upside)
$25.00 (41.08% Upside)
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.94%
12-Months-Change
Fundamentals
Return on Equity
-43.31%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
---
ANIK Company Deck
---
ANIK Earnings Call
Q3 2024
0:00 / 0:00
---
ANIK Stock 12 Month Forecast
Average Price Target
$25.00
▲(41.08% Upside)
Technical Analysis
Best Analysts Covering ANIK
1 Year
1 Year Success Rate
6/25 ratings generated profit
1 Year Average Return
-11.51%
reiterated a buy rating 26 days ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 24.00% of your transactions generating a profit, with an average return of -11.51% per trade.
---